Gallbladder cancer

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
11 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Kinase inhibitor 2 substances
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
Antimetabolite 1 substance
Monoclonal antibody (chimeric) 1 substance
Immunosuppressant 1 substance
Phase II: 2 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

2 trials
  • AstraZeneca AB Commercial
    BEVACIZUMAB; CISPLATIN; GEMCITABINE; INFLIXIMAB; LENVATINIB; MYCOPHENOLATE MOFETIL; RILVEGOSTOMIG; VOLRUSTOMIG
    2022-502317-29-00 2 countries 2023 n=60
    Ended
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting

Phase I

1 trial
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase II 0
Bayer Consumer Care AG Commercial 1 Phase II 1
New trials by year
2022
1
2023
1
2025
1
← All indication landscapes